Medpace Holdings, Inc. $MEDP Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 388,058 shares of the company’s stock after selling 26,090 shares during the period. Dimensional Fund Advisors LP owned about 1.38% of Medpace worth $199,496,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Quent Capital LLC acquired a new position in Medpace during the 3rd quarter worth about $25,000. Optiver Holding B.V. acquired a new position in Medpace in the 3rd quarter valued at about $27,000. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Employees Retirement System of Texas purchased a new stake in Medpace during the second quarter worth about $36,000. Finally, Root Financial Partners LLC purchased a new stake in Medpace during the third quarter worth about $38,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

MEDP stock opened at $470.59 on Monday. The business’s 50-day moving average is $533.94 and its two-hundred day moving average is $539.47. The firm has a market capitalization of $13.36 billion, a P/E ratio of 30.76, a P/E/G ratio of 2.26 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same period in the previous year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on MEDP. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a research note on Tuesday, February 10th. Truist Financial cut their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Leerink Partners reduced their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Finally, Mizuho set a $582.00 price target on shares of Medpace in a research note on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Medpace presently has an average rating of “Hold” and an average target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.